Werewolf Therapeutics Inc (NASDAQ: HOWL) on Monday, plunged -10.53% from the previous trading day, before settling in for the closing price of $1.14. Within the past 52 weeks, HOWL’s price has moved between $0.60 and $4.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -20.76%. The company achieved an average annual earnings per share of -6.99%. With a float of $33.12 million, this company’s outstanding shares have now reached $44.83 million.
The extent of productivity of a business whose workforce counts for 46 workers is very important to gauge. In terms of profitability, gross margin is 60.28%, operating margin of -4937.18%, and the pretax margin is -6335.17%.
Werewolf Therapeutics Inc (HOWL) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Werewolf Therapeutics Inc is 26.20%, while institutional ownership is 47.56%. The most recent insider transaction that took place on May 12 ’25, was worth 275,985. In this transaction Director of this company bought 320,913 shares at a rate of $0.86, taking the stock ownership to the 6,021,969 shares. Before that another transaction happened on May 14 ’25, when Company’s Director bought 162,539 for $0.98, making the entire transaction worth $159,288. This insider now owns 6,237,482 shares in total.
Werewolf Therapeutics Inc (HOWL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -6.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.68% during the next five years compared to -20.76% drop over the previous five years of trading.
Werewolf Therapeutics Inc (NASDAQ: HOWL) Trading Performance Indicators
Werewolf Therapeutics Inc (HOWL) is currently performing well based on its current performance indicators. A quick ratio of 8.09 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 40.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.64, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.72 in one year’s time.
Technical Analysis of Werewolf Therapeutics Inc (HOWL)
The latest stats from [Werewolf Therapeutics Inc, HOWL] show that its last 5-days average volume of 1.14 million was superior to 0.39 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 18.15%.
During the past 100 days, Werewolf Therapeutics Inc’s (HOWL) raw stochastic average was set at 42.30%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.94% in the past 14 days, which was lower than the 99.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0894, while its 200-day Moving Average is $1.5219. Now, the first resistance to watch is $1.0999. This is followed by the second major resistance level at $1.1799. The third major resistance level sits at $1.2198. If the price goes on to break the first support level at $0.9800, it is likely to go to the next support level at $0.9401. The third support level lies at $0.8601 if the price breaches the second support level.
Werewolf Therapeutics Inc (NASDAQ: HOWL) Key Stats
Market capitalization of the company is 45.77 million based on 44,874K outstanding shares. Right now, sales total 1,890 K and income totals -70,520 K. The company made 0 K in profit during its latest quarter, and -18,090 K in sales during its previous quarter.
